; Menarini Group – Product Pipeline Review – H2 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Menarini Group – Product Pipeline Review – H2 2011

VIEWS: 26 PAGES: 45

Menarini Group – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Menarini Group - Product Pipeline Review - H2 2011” provides data on the Menarini Group’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Menarini Group’s corporate website, SEC filings, investor presentations and featured press releases, both from Menarini Group and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Menarini Group - Brief Menarini Group overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Menarini Group human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Menarini Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Menarini Group’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Menarini Group’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Menarini Group in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Menarini Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunit

More Info
  • pg 1
									   Menarini Group – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01648CDB

                                                                                                 Publication Date: NOV 2011




Menarini Group – Product Pipeline Review – H2 2011                                          GMDHC01648CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Menarini Group – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 4
Menarini Group Snapshot ......................................................................................................................................................................................... 5
      Menarini Group Overview................................................................................................................................................................................... 5
      Key Information .................................................................................................................................................................................................. 5
      Key Facts ........................................................................................................................................................................................................... 5
Menarini Group – Research and Development Overview.......................................................................................................................................... 6
      Key Therapeutic Areas ....................................................................................................................................................................................... 6
Menarini Group – Pipeline Review ............................................................................................................................................................................ 8
      Pipeline Products by Stage of Development ....................................................................................................................................................... 8
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 9
      Pipeline Products – Combination Treatment Modalities .....................................................................................................................................10
Menarini Group – Pipeline Products Glance ............................................................................................................................................................11
      Menarini Group Clinical Stage Pipeline Products...............................................................................................................................................11
            Phase II Products/Combination Treatment Modalities .................................................................................................................................11
Menarini Group – Drug Profiles ...............................................................................................................................................................................12
      Amediplase .......................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      MEN16132 ........................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Sabarubicin .......................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      Sabarubicin + cisplatin ......................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
Menarini Group – Pipeline Analysis .........................................................................................................................................................................16
      Menarini Group – Pipeline Products by Therapeutic Class ................................................................................................................................16
      Menarini Group - Pipeline Products By Target...................................................................................................................................................17
      Menarini Group – Pipeline Products by Route of Administration ........................................................................................................................18
      Menarini Group – Pipeline Products by Molecule Type......................................................................................................................................19
Menarini Group – Recent Pipeline Updates ............................................................................................................................................................20
Menarini Group – Company Statement ....................................................................................................................................................................21
Menarini Group – Locations And Subsidiaries .........................................................................................................................................................22
      Head Office .......................................................................................................................................................................................................22
      Other Locations & Subsidiaries .........................................................................................................................................................................22
Recent Developments .............................................................................................................................................................................................24
            Dec 07, 2010: Menarini Completes Enrollment And Treatment Phase In Phase II Osteoarthritis Study.......................................................24
            Jun 01, 2002: Preparation For Phase III Clinicals: ProMetic And Menarini Biotech Achieve Milestone For Amediplase Manufacture ..........24




Menarini Group – Product Pipeline Review – H2 2011                                                                                                          GMDHC01648CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Menarini Group – Product Pipeline Review



            Jun 01, 1997: A Report From The European Organization For Research And Treatment Of Cancer, Early Clinical Studies Group .............25
Financial Deals Landscape......................................................................................................................................................................................26
      Menarini Group, Deals Summary ......................................................................................................................................................................26
Menarini Group, Pharmaceuticals & Healthcare, Deal Details..................................................................................................................................27
      Asset Transactions............................................................................................................................................................................................27
            PLIVA Sells AWD Manufacturing Plant In Germany ....................................................................................................................................27
      Partnerships .............................................................................................................................
								
To top